← Back to patent-cliff list
Levothyroxine Sodium
Tier C — Watch / tradeLevothyroxine Sodium
AbbVie
Originator
2000
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：THR
Brand：Euthyrox, Tirosint-Sol, Puran T4, Levo-T, Levothroid, Unithroid, Letrox, Synthroid, Eferox, Eutirox, Levoxyl, Novothyrox
Indications (approved)：Coma, 粘液性水肿昏迷, Hypothyroidism, Thyroid cancer, Hyperthyroidism
Regional status
US
Approved
2000-08-21
EU
Phase III
2004-03-01
China
Approved
2000-01-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Levothyroxine Sodium?
Approved indications include: Coma, 粘液性水肿昏迷, Hypothyroidism, Thyroid cancer, Hyperthyroidism.
When does the Levothyroxine Sodium patent expire?
No public expiry year is available for Levothyroxine Sodium yet; this page updates once verified.
How do I get a quote for Levothyroxine Sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27